Tox Free Solutions. Winning work again A$2.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Similar documents
SG Fleet Group. Another UK acquisition. Earnings and target price revision

SG Fleet Group % growth in FY17. Earnings and target price revision. Price catalyst. Catalyst: Results and contract wins.

Eclipx Group. Highlights its funding flexibility A$3.77 AUSTRALIA. Event. Impact. Earnings and target price revision.

Automotive Holdings Group

Silver Chef. Capital raising A$7.71 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Platinum Asset Management

Cardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.

QBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision

NIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Seek. Progresses Zhaopin privatisation A$16.33 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Oil Search. Proving up PNG A$7.11 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Ramsay Health Care. France begins to bite A$66.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Spotless Group Holdings

Boart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation

Sims Metal Management

Southern Cross Media. Streamlining ahead of reform? A$1.37 AUSTRALIA

Fisher & Paykel Healthcare

Cochlear. Roberts replaced A$88.66 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Bendigo and Adelaide Bank

National Australia Bank

Downer EDI Two out of three ain t bad Event

Sirtex Medical. Healthy dose sales. Earnings and target price revision. Price catalyst. Catalyst: FY16 result on the 24th of August

Whitehaven Coal. China outlook drives impairments A$1.04 AUSTRALIA. Event. Impact. Earnings and target price revision.

CIMIC Group. Earnings and target price revision. No change. Price catalyst. Catalyst: Q1 earnings 13 April. Action and recommendation

Oz Minerals. On track to meet guidance A$6.51 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Premier Investments. Making a move? A$14.18 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Telstra Corporation. Vodafone better, but far from good A$6.43 AUSTRALIA. Event. Impact. Earnings and target price revision.

Super Retail Group (SUL AU) Are we there yet?

Challenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation

Senex Energy Production and revenue unsurprised, cash builds on lower capex

Meridian Energy. On tax depreciation NZ$2.08 NEW ZEALAND. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Origin Energy. 4Q Production. ORG reported its 4 th quarter production report, following on ConocoPhilips quarterly result.

Coca-Cola Amatil. Not as fizzy as it looks A$8.78 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Kingsgate Consolidated

Orocobre. Upside exposure fading. Earnings and target price revision. Price catalyst. Catalyst: Update on projects or Q1 report

ANZ Bank. The Dis-Associates. Earnings and target price revision. No change. Price catalyst. Catalyst: 3Q15 Trading Update. Action and recommendation

UGL. Driving growth in DTZ. Earnings and target price revision. No change. Price catalyst. Action and recommendation

Karoon Gas. What a difference a day makes A$1.63 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Nuplex Industries. Should benefit from a weak Kiwi NZ$4.55 NEW ZEALAND. Event. Impact. Earnings and target price revision.

Generation Healthcare REIT

Oz Minerals. Solid start to the year A$5.62 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Fisher & Paykel Healthcare

3P Learning. Coming to America... A$2.55 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

NEW ZEALAND Price Valuation NZ$ 1.74 Event 12-month target NZ$ month TSR % -10.1

Asaleo Care. NZ$ pulped. We review the outlook for Asaleo. Earnings and target price revision. Price catalyst. Catalyst: CY15 results.

Kiwi Property Group. Land banking for the future NZ$1.43 NEW ZEALAND. Event. Impact. Earnings and target price revision.

Perseus Mining. Revised Sissingué plan A$0.31 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Healthcare. Currency adjustments AUSTRALIA. Event. Impact. Outlook COH 8.0% RMD 6.9% CSL 6.0% ANN 5.0% SHL 2.6%

Vista Group International

Auckland International Airport

Sandfire Resources. Swings to net cash A$5.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Pilbara Minerals (PLS AU) Ramp-up gaining traction

Regis Resources. Strong 1H15 result A$1.29 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Fortescue Metals Group

Austal. Retail take up 62% Earnings and target price revision. Price catalyst. Action and recommendation

PanAust. Larger impairment and dividend cut A$1.35 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Genworth Mortgage Insurance Australia

Carsales.com. Motoring along nicely A$10.23 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Ramsay Health Care (RHC AU) RHC UK on the mend?

Dexus Property Group. Infra driving industrial demand A$9.94 AUSTRALIA. Event. Impact. Earnings and target price revision.

SingTel. Earnings and target price revision. Price catalyst. Action and recommendation. Maintain Outperform.

Filling in the gaps. Earnings and target price revision. Price catalyst. Action and recommendation

Greencross. Check up. We review the outlook for GXL. Earnings and target price revision. Price catalyst. Catalyst: FY15/6 results

Independence Group NL

ANZ Bank. What execution risk? Earnings and target price revision. Price catalyst. Catalyst: 1Q17 Trading update, February 2017.

AUSTRALIA Price Valuation A$ Event 12-month target A$ month TSR % +6.9 Volatility Index Medium

Automotive Holdings Group

SingTel. Optus rises A$3.98 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Iron Mountain. US$10 worth Recalling at investor day US$31.83 UNITED STATES. Event. Impact. Earnings and target price revision.

Silver Lake Resources

Aconex. Cornering the domestic market A$4.40 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Australian Banks. Pre-Reporting Form Guide AUSTRALIA. Event. Impact. Outlook

Oz Minerals. Raises copper production outlook A$9.08 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

AMP. Earnings and target price revision. No change. Price catalyst. Action and recommendation

Australian Mobile Market

Earnings and target price revision. Price catalyst. Catalyst: 1H14 result in February Action and recommendation

Karoon Gas. Losing the deal A$1.83 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

AUSTRALIA Price Valuation A$ 7.52 Event 12-month target A$ month TSR % +3.4

Aussie Macro Moment. Budget 16/17 careful consolidation AUSTRALIA. Event. Impact. Outlook

Genesis Energy. A 9% FCF yield and you call underperform? NZ$1.71 NEW ZEALAND. Event. Impact. Earnings and target price revision.

Australian Banks. Money Talks vertically challenged AUSTRALIA. Inside. Majors average short positions and banks index

Aust. General Insurance

Aged Care. Propco sale & lease back A$2.71 A$5.75 A$6.15 AUSTRALIA. Event. Impact. Outlook

Saracen Mineral Holdings

AUSTRALIA Price Event Valuation A$ month target A$ 5.20

Fisher & Paykel Healthcare

Ryman Healthcare. Arrested development NZ$9.60 NEW ZEALAND. Event. Impact. Earnings and target price revision. Price catalyst

Australian Banks. If it s too good to be true AUSTRALIA. Event. Impact. Outlook. Impact of repricing and capital from additional 10% investor RWA

Newcrest Mining. Strong production result A$21.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Adelaide Brighton. Overcoming headwinds A$5.45 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Aventus Retail Property Fund

CSL. New competitor on the block A$89.68 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

BHP Billiton. Mad Dog 2 gets FID AUSTRALIA/ UNITED KINGDOM/ SOUTH AFRICA. Event. Impact. Earnings and target price revision.

Australian Banks. Funding markets open for now

Clough. Forge assisted. Earnings and target price revision. Price catalyst. Action and recommendation

Nine Entertainment Co.

National Australia Bank

Crown Resorts. A favourable risk/reward setting A$12.94 AUSTRALIA. Event. Impact. Earnings and target price revision.

Premier Investments. Smiggle proving a four leaf clover A$13.79 AUSTRALIA. Event. Impact. Earnings and target price revision.

Transcription:

AUSTRALIA TOX AU Price (at 05:10, 30 Nov 2016 GMT) Outperform A$2.34 Valuation - EV/EBITDA A$ 2.52-3.07 12-month target A$ 2.79 12-month TSR % +23.1 Volatility Index Medium GICS sector Commercial & Professional Services Market cap A$m 424 30-day avg turnover A$m 1.2 Number shares on issue m 181.4 Investment fundamentals Year end 30 Jun 2016A 2017E 2018E 2019E Revenue m 393.4 495.3 557.8 579.3 EBIT m 39.0 47.3 57.6 60.5 Reported profit m 12.6 25.9 31.6 33.9 Adjusted profit m 24.7 30.2 37.0 39.1 Gross cashflow m 56.8 69.2 80.2 83.9 CFPS 40.9 40.1 41.4 43.3 CFPS growth % 2.0-2.0 3.3 4.6 PGCFPS x 5.7 5.8 5.7 5.4 PGCFPS rel x 0.49 0.61 0.63 0.67 EPS adj 17.8 17.2 19.1 20.2 EPS adj growth % -2.1-3.5 11.0 5.7 PER adj x 13.1 13.6 12.3 11.6 PER rel x 0.67 0.88 0.89 0.96 Total DPS 8.9 9.0 9.0 9.5 Total div yield % 3.8 3.8 3.8 4.1 Franking % 100 100 100 100 ROA % 8.6 7.9 8.0 8.2 ROE % 9.5 9.0 9.2 9.4 EV/EBITDA x 6.1 6.2 5.2 5.0 Net debt/equity % 36.9 38.2 35.3 27.5 P/BV x 1.3 1.1 1.1 1.1 TOX AU vs Small Ordinaries, & rec history Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, November 2016 (all figures in AUD unless noted) 30 November 2016 Macquarie Securities (Australia) Limited Winning work again Event Macquarie attended the Toxfree AGM in Perth. Impact New contract wins. Toxfree has been awarded a five-year contract with INPEX for the operational phase of Ichthys and a three-year contract for upstream works at the GLNG plant. Together with the retention of the Fortescue and APLNG contracts the core business is on a stronger footing heading into FY18. No update on the Chevron contract. There was no update on the status of the Chevron contract (see our 18 May note Chevron under review for more detail). Given the impending completion of construction at Barrow Island and continued delays in awarding the new contract, we believe this is becoming a less material issue for Toxfree and is a factor in us re-upgrading our recommendation to Outperform. Earnings should still grow in FY17 driven by the Daniels and Worth acquisitions. Worth and Daniels are both expected to add ~$9-10m in incremental EBITDA in FY17. Also Toxfree has won a five-year contract with BHP at Olympic Dam, which commenced in June. In addition, the tender pipeline remains high. Trading conditions are expected to remain challenging in FY17, especially as Gorgon volumes continue to decline. Longer term, we expect LNG volumes to increase as the new WA plants commence production. Strong cost performance is also helping to support earnings. Balance sheet remains solid. Pro forma net debt is $159.3m. We expect FY18 (the first full year post Daniels) net debt to EBITDA to be ~1.4x. Earnings and target price revision No change to EPS forecasts. Price target changed from $2.52 to $2.79. Our price target is based on 6.5x EBITDA (previously 6.0x). This is a discount to the 7.0x we use to value peer company Cleanaway. Price catalyst 12-month price target: A$2.79 based on an EV/EBITDA methodology. Catalyst: Contract awards and earnings delivery. Action and recommendation Upgrade to Outperform. We are encouraged by the return of multiple contract wins in the core business and the relative decline in the importance of the Barrow Island contract. Toxfree is inexpensive considering earnings now appear to be on a stronger footing. Please refer to page 4 for important disclosures and analyst certification, or on our website www.macquarie.com/research/disclosures.

(TOX:$2.34) 30-Nov-16 Interim results 2H15(a) 1H16(a) 2H16(a) 1H17(e) Profit & Loss 2016A 2017E 2018E 2019E Revenue 200.0 197.7 195.7 217.5 Revenue $m 393.4 495.3 557.8 579.3 EBITDA $m 34.4 37.9 34.7 39.8 EBITDA $m 72.5 90.1 105.7 110.0 Depreciation $m 15.2 15.4 16.2 19.3 Depreciation $m 31.6 38.5 42.8 44.3 Amortisation of goodwill $m 0.9 0.8 1.1 2.2 Amortisation of goodwill $m 1.9 4.3 5.4 5.2 EBIT $m 18.3 21.6 17.4 18.4 EBIT $m 39.0 47.3 57.6 60.5 Net Interest expense $m 3.1 3.2 2.7 4.2 Net interest expense $m 5.8 8.4 10.3 10.0 Pre-Tax Profit $m 15.2 18.5 14.7 14.2 Pre-Tax Profit $m 33.2 38.9 47.3 50.5 Tax Expense $m 4.6 5.5 4.4 4.7 Tax Expense $m 10.0 12.5 15.3 16.1 Net Profit $m 10.7 12.9 10.3 9.5 Net Profit $m 23.3 26.4 32.0 34.3 Outside equity interests $m 0.3 0.4 0.1 0.2 Outside equity interests $m 0.4 0.4 0.4 0.4 Net Abn/Extra $m -1.0 0.0-10.2 0.0 Net Abnormals/Extra. $m -10.2 0.0 0.0 0.0 Reported Earnings $m 9.4 12.6 0.0 9.2 Reported Earnings $m 12.6 25.9 31.6 33.9 Adjusted Earnings $m 11.2 13.4 11.4 11.4 Adjusted Earnings $m 24.7 30.2 37.0 39.1 Gross Cashflow $m 28.4 30.5 27.2 30.9 Gross Cashflow $m 57.7 71.8 83.0 84.7 EPS (Adj/dil) c 8.3 9.9 8.2 7.5 EPS (adj/diluted) c 18.1 17.5 19.1 20.2 EPS growth % -0.2-2.1-2.2-24.8 EPS growth % -2.3% -3.4% 9.3% 5.7% CFPS c 32.3 21.9 21.5 20.5 PE (adj) x 12.9 13.4 12.3 11.6 CFPS Growth % 95.6 65.5-33.5-6.6 CFPS c 43.4 37.1 38.6 42.3 EBITDA/Sales % 17.2 19.2 17.7 18.3 CFPS Growth % -4.7-14.5 3.9 9.7 EBIT/Sales % 9.2 10.9 8.9 8.5 PGCFPS x 5.4 6.3 6.1 5.5 Earnings Split % 45.1 54.1 45.9 37.7 DPS c 9.0 9.0 9.0 9.5 Revenue Growth % 9.9-4.6-2.2 10.0 Yield % 3.8 3.8 3.8 4.1 EBIT Growth % 4.0 4.2-5.2-14.9 Franking % 100.0 100.0 100.0 100.0 Profit and Loss ratios 2016A 2017E 2018E 2019E Cashflow Analysis 2016A 2017E 2018E 2019E Revenue Growth % -3.4 25.9 12.6 3.9 EBIT Growth % -0.2 21.2 21.8 5.1 Pre-tax Profit $m 33.2 38.9 47.3 50.5 EBITDA/Sales % 18.4 18.2 19.0 19.0 Depreciation & Amortisation $m 33.5 42.8 48.2 49.5 EBIT/Sales % 9.9 9.5 10.3 10.4 Tax Paid $m -9.0-10.0-12.5-15.3 Effective tax rate % 30.0 32.2 32.3 32.0 Gross cashflow $m 57.7 71.8 83.0 84.7 Payout ratio % 49.8 51.5 47.2 47.1 Changes in working capital $m 4.1-5.0-5.5-1.9 EV/EBITA x 10.3 10.8 9.5 8.7 Other $m -2.4-2.6-2.8-0.9 EV/EBITDA x 5.8 6.2 5.7 5.2 Operating Cashflow $m 59.4 64.2 74.7 82.0 EV/Sales x 1.1 1.1 1.1 1.0 Acquisitions $m -68.6-195.5 0.0 0.0 Capex - Plant & Equip. $m -32.0-30.0-50.8-35.7 Balance sheet ratios Asset Sales $m 8.6 0.0 0.0 0.0 ROE % 9.5 9.0 9.2 9.4 Other $m 0.0 14.0 0.0 0.0 ROA % 8.6 7.9 8.0 8.2 Investing cashflow $m -91.9-211.5-50.8-35.7 ROFE % 11.1 10.2 10.4 11.0 Dividend (ordinary) $m -11.3-17.4-17.4-18.4 Net Debt $m 101.9 152.6 146.1 118.2 Equity raised $m 23.2 114.0 0.0 0.0 Net Debt/Equity % 36.9 38.2 35.3 27.5 Other $m 0.0 0.0 0.0 0.0 Interest Cover x 6.7 5.6 5.6 6.0 Financing cashflow $m 11.9 96.6-17.4-18.4 Price/NTA x 3.6 2.1 1.9 1.7 NTA per share $ 0.65 1.14 1.24 1.34 Net Change in cash/debt $m -20.6-50.7 6.5 27.8 EFPOWA m 136.8 173.0 193.8 193.8 Historical performance 2013A 2014A 2015A 2016A Balance Sheet 2016A 2017E 2018E 2019E Cash $m 32.0 62.8 69.3 97.1 Revenue $m 284.7 370.0 407.3 393.4 Receivables $m 90.9 109.5 123.3 128.1 EBITDA $m 57.7 66.3 70.8 72.5 Inventories $m 0.6 0.7 0.8 0.9 Depreciation/Amortisation $m 22.3 27.4 31.7 33.5 Investments $m 0.0 181.5 181.5 181.5 EBIT $m 35.4 38.8 39.1 39.0 Property, plant & equipment $m 175.9 167.4 175.4 166.8 Net interest expense $m 5.1 6.1 6.3 5.8 Intangibles $m 180.2 175.9 170.5 165.3 Pre-Tax Profit $m 30.3 32.7 32.8 33.2 Other Assets $m 11.4 11.4 11.4 11.4 Tax Expense $m 8.6 9.7 9.8 10.0 Total Assets $m 491.0 709.2 732.3 751.1 Net Profit $m 21.7 23.0 23.0 23.3 Payables $m 53.2 67.0 75.4 78.4 Net Abn/Extra $m -8.1-1.3-1.0-10.2 Short Term Debt $m 3.6 3.6 3.6 3.6 Long Term Debt $m 130.3 211.8 211.8 211.8 EPS (adj/dil) c 19.6 19.2 18.5 18.1 Other Liabilities $m 27.6 27.6 27.6 27.6 EPS growth % 0.3 0.0 0.0 0.0 Total Liabilities $m 214.6 309.9 318.3 321.3 Ordinary DPS c 5.0 6.0 8.5 9.0 Shareholders Funds $m 273.4 395.9 410.0 425.5 EBITDA/Sales % 20.2 17.9 17.4 18.4 Minority Interests $m 3.0 3.4 3.9 4.3 EBIT/Sales % 12.4 10.5 9.6 9.9 Total Shareholders Equity $m 276.4 399.3 413.9 429.9 ROE % 12.3 11.2 10.2 9.5 ROFE % 13.6 12.3 12.1 11.1 Total Funds employed $m 491.0 709.2 732.3 751.1 EFPOWA m 122.0 134.5 134.5 136.8 2016A 2017E 2018E 2019E 2016A 2017E 2018E 2019E Sales 393.4 495.3 557.8 579.3 EBITA ND/EBITDA x 1.4 1.7 1.4 1.1 Industrial Services 9.0 9.2 9.5 9.8 EBITDA/Net Interest x 12.5 10.7 10.3 11.0 Waste Services (Solid Waste 41.9 36.1 37.2 38.3 Hazardous Waste (incl Liquid 14.6 12.4 13.1 13.7 Wanless 0.0 9.1 9.6 10.0 Other -24.6-25.3-26.0-26.8 Total 40.9 41.6 43.3 45.0 Margin 10.4% 8.4% 7.8% 7.8% Source: Company data, Macquarie Research, November 2016 30 November 2016 2

Macquarie Quant View The quant model currently holds a reasonably negative view on Tox Free Solutions. The strongest style exposure is Valuations, indicating this stock is under-priced in the market relative to its peers. The weakest style exposure is Earnings Momentum, indicating this stock has received earnings downgrades and is not well liked by sell side analysts. 290/351 Global rank in Comm. & Prof. Services % of BUY recommendations 27% (3/11) Number of Price Target downgrades 2 Number of Price Target upgrades 1 Fundamentals Attractive Quant Local market rank Global sector rank Displays where the company s ranked based on the fundamental consensus Price Target and Macquarie s Quantitative Alpha model. Two rankings: Local market (Australia & NZ) and Global sector (Comm. & Prof. Services) Macquarie Alpha Model ranking A list of comparable companies and their Macquarie Alpha model score (higher is better). Factors driving the Alpha Model For the comparable firms this chart shows the key underlying styles and their contribution to the current overall Alpha score. 0.9-0.6-2.1-3.0-2.0-1.0 0.0 1.0 2.0 3.0-100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% Valuations Growth Profitability Earnings Momentum Price Momentum Quality Macquarie Earnings Sentiment Indicator The Macquarie Sentiment Indicator is an enhanced earnings revisions signal that favours analysts who have more timely and higher conviction revisions. Current score shown below. Drivers of Stock Return Breakdown of 1 year total return (local currency) into returns from dividends, changes in forward earnings estimates and the resulting change in earnings multiple. 0.4 0.5-0.6-3.0-2.0-1.0 0.0 1.0 2.0 3.0-40% -30% -20% -10% 0% 10% 20% 30% 40% Dividend Return Multiple Return Earnings Outlook 1Yr Total Return What drove this Company in the last 5 years Which factor score has had the greatest correlation with the company s returns over the last 5 years. IRR Dividend Disc. Model Dividend Cover Return on Assets FY1 Net Income Margin FY0 Price to Sales LTM DPS Growth 5yr Historic Capex Growth Earnings Stability -35% Negatives Positives -20% -24% -24% 32% 31% 30% 36% -40% -20% 0% 20% 40% How it looks on the Alpha model A more granular view of the underlying style scores that drive the alpha (higher is better) and the percentile rank relative to the sector and market. Alpha Model Score Valuation Growth Profitability Earnings Momentum Price Momentum Quality Capital & Funding Liquidity Risk Technicals & Trading Normalized Score -0.56 0.24 0.13-0.04-0.83-0.30 0.08-0.37-0.65-0.06-0.49 Percentile relative to sector(/351) Percentile relative to market(/423) 0 50 100 0 50 100 0 0 1 1 Source (all charts): FactSet, Thomson Reuters, and Macquarie Research. For more details on the Macquarie Alpha model or for more customised analysis and screens, please contact the Macquarie Global Quantitative/Custom Products Group (cpg@macquarie.com) 30 November 2016 3

Important disclosures: Recommendation definitions Macquarie - Australia/New Zealand Outperform return >3% in excess of benchmark return Neutral return within 3% of benchmark return Underperform return >3% below benchmark return Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield Macquarie Asia/Europe Outperform expected return >+10% Neutral expected return from -10% to +10% Underperform expected return <-10% Macquarie South Africa Outperform expected return >+10% Neutral expected return from -10% to +10% Underperform expected return <-10% Macquarie - Canada Outperform return >5% in excess of benchmark return Neutral return within 5% of benchmark return Underperform return >5% below benchmark return Macquarie - USA Outperform (Buy) return >5% in excess of Russell 3000 index return Neutral (Hold) return within 5% of Russell 3000 index return Underperform (Sell) return >5% below Russell 3000 index return Volatility index definition* This is calculated from the volatility of historical price movements. Very high highest risk Stock should be expected to move up or down 60 100% in a year investors should be aware this stock is highly speculative. High stock should be expected to move up or down at least 40 60% in a year investors should be aware this stock could be speculative. Medium stock should be expected to move up or down at least 30 40% in a year. Low medium stock should be expected to move up or down at least 25 30% in a year. Low stock should be expected to move up or down at least 15 25% in a year. * Applicable to Asia/Australian/NZ/Canada stocks only Recommendations 12 months Note: Quant recommendations may differ from Fundamental Analyst recommendations Financial definitions All "Adjusted" data items have had the following adjustments made: Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests EPS = adjusted net profit / efpowa* ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards). Recommendation proportions For quarter ending 30 September 2016 AU/NZ Asia RSA USA CA EUR Outperform 47.26% 55.50% 38.46% 45.47% 59.09% 48.21% (for US coverage by MCUSA, 8.20% of stocks followed are investment banking clients) Neutral 38.01% 29.31% 42.86% 48.77% 37.88% 36.79% (for US coverage by MCUSA, 8.25% of stocks followed are investment banking clients) Underperform 14.73% 15.19% 18.68% 5.76% 3.03% 15.00% (for US coverage by MCUSA, 8.00% of stocks followed are investment banking clients) TOX AU vs Small Ordinaries, & rec history (all figures in AUD currency unless noted) Note: Recommendation timeline if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, November 2016 12-month target price methodology TOX AU: A$2.79 based on a EV/EBITDA methodology Company-specific disclosures: Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures. Date Stock Code (BBG code) Recommendation Target Price 27-Oct-2016 TOX AU Neutral A$2.48 23-Aug-2016 TOX AU Neutral A$2.61 18-May-2016 TOX AU Neutral A$2.86 21-Mar-2016 TOX AU Outperform A$3.40 20-Aug-2015 TOX AU Outperform A$3.33 24-Feb-2015 TOX AU Outperform A$3.04 22-Jan-2015 TOX AU Outperform A$3.09 20-Aug-2014 TOX AU Outperform A$3.07 17-Jun-2014 TOX AU Outperform A$3.25 26-Feb-2014 TOX AU Outperform A$3.52 Target price risk disclosures: TOX AU: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures. Analyst certification: We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Limited (MGL) total revenues, a portion of which are generated by Macquarie Group s Investment Banking activities. General disclosure: This research has been issued by Macquarie Securities (Australia) Limited ABN 58 002 832 126, AFSL 238947, a Participant of the ASX and Chi-X Australia Pty Limited. This research is distributed in Australia by Macquarie Wealth Management, a division of Macquarie Equities Limited ABN 41 002 574 923 AFSL 237504 ("MEL"), a Participant of the ASX, and in New Zealand by Macquarie Equities New Zealand Limited ( MENZ ) an NZX Firm. Macquarie Private Wealth s services in New Zealand are provided by MENZ. Macquarie Bank Limited (ABN 46 008 583 542, AFSL No. 237502) ( MBL ) is a company incorporated in Australia and authorised under the Banking Act 1959 (Australia) to conduct banking business 30 November 2016 4

This publication was disseminated on 30 November 2016 at 08:59 UTC. Macquarie Wealth Management in Australia. None of MBL, MGL or MENZ is registered as a bank in New Zealand by the Reserve Bank of New Zealand under the Reserve Bank of New Zealand Act 1989. Apart from Macquarie Bank Limited ABN 46 008 583 542 (MBL), any MGL subsidiary noted in this research,, is not an authorised deposit-taking institution for the purposes of the Banking Act 1959 (Australia) and that subsidiary s obligations do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of that subsidiary, unless noted otherwise. This research contains general advice and does not take account of your objectives, financial situation or needs. Before acting on this general advice, you should consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision. This research has been prepared for the use of the clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient, you must not use or disclose this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. This research is based on information obtained from sources believed to be reliable, but the Macquarie Group does not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. The Macquarie Group accepts no liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. The Macquarie Group produces a variety of research products, recommendations contained in one type of research product may differ from recommendations contained in other types of research. The Macquarie Group has established and implemented a conflicts policy at group level, which may be revised and updated from time to time, pursuant to regulatory requirements; which sets out how we must seek to identify and manage all material conflicts of interest. The Macquarie Group, its officers and employees may have conflicting roles in the financial products referred to in this research and, as such, may effect transactions which are not consistent with the recommendations (if any) in this research. The Macquarie Group may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case. The Macquarie Group s employees or officers may provide oral or written opinions to its clients which are contrary to the opinions expressed in this research. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures Macquarie Group 30 November 2016 5